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Oxidative phosphorylationGlobal or local ischemia contributes to the pathogenesis of acute kidney injury (AKI). Currently there are no
speciﬁc therapies to prevent AKI. Potentiation of glycolytic metabolism and attenuation of mitochondrial respira-
tion may decrease cell injury and reduce reactive oxygen species generation from the mitochondria. Meclizine,
an over-the-counter anti-nausea and -dizziness drug, was identiﬁed in a ‘nutrient-sensitized’ chemical screen. Pre-
treatment with 100 mg/kg of meclizine, 17 h prior to ischemia protected mice from IRI. Serum creatinine levels at
24 h after IRI were 0.13 ± 0.06 mg/dl (sham, n = 3), 1.59 ± 0.10 mg/dl (vehicle, n = 8) and 0.89 ± 0.11 mg/dl
(meclizine, n = 8). Kidney injury was signiﬁcantly decreased in meclizine treated mice compared with vehicle
group (p b 0.001). Protectionwas also seenwhenmeclizinewas administered 24 h prior to ischemia. Meclizine re-
duced inﬂammation,mitochondrial oxygen consumption, oxidative stress,mitochondrial fragmentation, and tubu-
lar injury. Meclizine preconditioned kidney tubular epithelial cells, exposed to blockade of glycolytic and oxidative
metabolism with 2-deoxyglucose and NaCN, had reduced LDH and cytochrome c release. Meclizine upregulated
glycolysis in glucose-containing media and reduced cellular ATP levels in galactose-containing media. Meclizine
inhibited the Kennedy pathway and caused rapid accumulation of phosphoethanolamine. Phosphoethanolamine
recapitulated meclizine-induced protection both in vitro and in vivo.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acute kidney injury (AKI) is a common clinical problem associated
with an increasing prevalence, highmorbidity,mortality, and prolonged
length of hospitalization (Hsu et al., 2007; Lameire et al., 2005; Xue
et al., 2006). AKI is also a risk factor for progression to chronic kidney
disease (CKD) (Siew and Deger, 2012; Lo et al., 2009; Wald et al.,
2009; Ferenbach and Bonventre, 2015; Canaud and Bonventre, 2015).
Global or local ischemia contributes to the pathogenesis of AKI which
complicates various clinical conditions. Ischemia-reperfusion injury
(IRI) is also a risk factor for delayed graft function and chronic allograft
nephropathy (Wirthensohn and Guder, 1986; Brezis et al., 1984;
Fletcher et al., 2009). As the options to prevent AKI are few and its prog-
nosis is poor, novel interventional strategies are needed. Episodes ofne, Room 576, 4 Blackfan Circle,
J.V. Bonventre).
hysics, TAMU3474, Texas A&M
nt of Biochemistry, Ludwig-
81377 Munich, Germany.
. This is an open access article undernonlethal ischemia can precondition the kidney protecting it against
subsequent ischemia (Park et al., 2001; Joo et al., 2006; Ali et al., 2007;
Bonventre, 2002). It would be highly desirable to mimic ischemic pre-
conditioning with pharmaceutical intervention.While there are studies
reporting that agents, such as high mobility group box 1 (HMGB1) (Wu
et al., 2014), isoﬂurane (Su et al., 2014), inhibitors of hypoxia inducible
transcription factor (HIF) or carbon monoxide (Bernhardt et al., 2006)
given to animals prior to the ischemic event are protective, in most
studies the agents are administered close to the time of IRI. Furthermore
the effects are not keep in sustained if givenmore than a fewhours prior
to the IRI, nor are the mechanisms understood.
Ischemia plays a central role in the initiation and establishment of
AKI because the nephron has a high energy demand and intrarenal ox-
ygen tensions in the outer medulla are low and further reduced by hy-
poperfusion (Brezis and Rosen, 1995). The kidney proximal tubular
epithelial cells are particularly sensitive to IRI because they have mini-
mal glycolytic capacity and rely on mitochondrial metabolism for ATP
synthesis (Wirthensohn and Guder, 1986; Klein et al., 1981; Uchida
and Endou, 1988). In addition, in the setting of tubular cell injury, mito-
chondrial respiration can result in the generation of oxidants. Therefore,
shifting energymetabolism frommitochondrial respiration to glycolysis
could be a viable therapeutic strategy to minimize cell injury.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1091S. Kishi et al. / EBioMedicine 2 (2015) 1090–1101Meclizine was identiﬁed by using a small molecule screening strate-
gy to identify clinically useful drugs that are capable of shifting cellular
energy metabolism from respiration to glycolysis (Gohil et al., 2010).
Meclizine is an “over-the-counter” FDA approved histamine receptor
blocker used for the treatment of nausea, vomiting, and dizziness
associated with motion sickness and has been used for many decades.
Meclizine shifts cellular energy metabolism frommitochondrial respira-
tion to glycolysis (Wirthensohn and Guder, 1986), via direct targeting of
cytosolic phosphoethanolamine metabolism (Gohil et al., 2013). We
found that meclizine reduced inﬂammation, mitochondrial oxygen
consumption, oxidative stress, mitochondrial fragmentation and tubular
injury after kidney IRI. Meclizine pretreatment of HK-2 cells reduced
NaCN-induced LDH release, cytochrome c release and mitochondrial-
dependent ATP production and increased lactate production. In addition,
meclizine inhibited the Kennedy pathway and led to rapid accumulation
of phosphoethanolamine. Exogenous addition of ethanolamine in vivo
and in vitro was protective, suggesting that meclizine mediated protec-
tion occurs via cytosolic phosphoethanolamine metabolism. Thus, our
study not only offers a clinically used drug as a potential therapeutic
agent but also identiﬁes a previously unidentiﬁed pathway that can be
targeted for kidney IRI.2. Material & Methods
2.1. Animal Experiments
All mouse studies followed the fundamental guidelines for Animal
Care and Use in Research and Education and were performed in
accordance with the animal use protocol approved by the Institu-
tional Animal Care and Use Committee of Harvard Medical School.
Experiments were performed in 8–10 wk old male C57BL/6 mice
purchased from Charles River Laboratories. Animals were anesthetized
with sodium pentobarbital (60 mg/kg body weight intraperitoneally)
prior to surgery. Kidneyswere exposed through ﬂank incisions and ren-
dered ischemic by clamping the renal pedicles with nontraumatic
clamps (Roboz, Rockville, MD). After 27 min at 36.5–37 °C the clamps
were removed.Malemicewere used because they aremore susceptible
to ischemia and have a more consistent response to ischemia (Park
et al., 2004). Successful renal ischemia and reperfusion was document-
ed by visual inspection of the kidney. Blood pressurewas notmonitored
in this study. Two hours after surgery, 1 ml of NaCl 0.9% was adminis-
tered intraperitoneally. Some animals were subjected to sham surgery.
In the toxin AKI models mice received a one-time intraperitoneal injec-
tion of cisplatin (25 mg/kg body weight, Sigma-Aldrich, St. Louis, MO,
USA) or aristolochic acid (10 mg/kg body weight, Sigma-Aldrich) in
NaCl 0.9%. The control group was administered NaCl 0.9% only. Mecli-
zine or vehicle (10% Kolliphor® EL in PBS) was administered intraperi-
toneally at different doses and different time-points.
For the dose–response experiment, mice received 10, 30, 60 or
100 mg/kg body weight of meclizine 17 h and 3 h before IRI. For
the time-course experiment, one injection of meclizine
(100 mg/kg) was given 8, 17 or 24 h before IRI. For preconditioning
experiments, 100 mg/kg of meclizine was injected 17 h before IRI.
Some mice received two injections of meclizine (100 mg/kg) 0
(after removing clamps) and 8 h after IRI. Other animals were
injected with ethanolamine (150 mg/kg body weight of ethanol-
amine, Sigma-Aldrich), pH 7.4 in phosphate buffered saline (PBS)
or vehicle (PBS) administered intraperitoneally 2 h before, immedi-
ately after and 24 h after IRI. Mice were sacriﬁced 24 or 48 h after re-
lease of the pedicle clamps, 3 days after cisplatin injection or 5 days
after aristolochic acid, and 48 h after ethanolamine injection for tis-
sue analysis. Mice were randomly divided into experimental groups.
Serum creatinine was measured in all mice. Before sacriﬁce, some
animals were placed in metabolic cages for 3 h to collect urine for
kidney injury molecule-1 (KIM-1) measurement.2.2. Renal Function
Serum creatininewasmeasured by the picric-acid method using the
Beckman Creatinine Analyzer II (Beckman, Brea, CA). Serum blood urea
nitrogen (BUN) was measured using the Inﬁnity Urea Kit (Thermo
Scientiﬁc, West Sussex, UK).
2.3. KIM-1 Measurement
Urine KIM-1 concentration was measured using the Luminex xMAP
technology (Vaidya et al., 2011). Brieﬂy, 30 μl of urine sample was incu-
batedwith ~6000 anti-mouse KIM-1-coupled beads/well for 1 h follow-
ed by 3 washes with PBS-Tween 20 (PBST). Beads were then incubated
with biotinylated KIM-1 detection antibody for 45 min and washed
again 3 times with PBST. Quantiﬁcation was achieved by incubating
samples with picoerythrin-coupled streptavidin (Invitrogen) and excit-
ing at 532nm. The signal from thisﬂuorochromewas detected using the
Bio-Plex 200 system (BioRad) and is directly proportional to the amount
of antigen bound to themicrobead surface. Data were interpreted using
a 13-point standard ﬁve parametric logistic regression model. All sam-
ples were analyzed in triplicate and the intra-assay variability was less
than 5%.
2.4. Histology
Kidneys were ﬁxed in 10% formalin overnight and then placed into
70% ethanol. Parafﬁn sections of embedded kidneys were stained with
hematoxylin and eosin (H&E) and scored in a blinded fashion. The
acute tubular necrosis score was determined by quantitating detach-
ment of epithelial cells, loss of brush border, cast formation, inﬂamma-
tory cell inﬁltrate and scored from 0 to 4 based on the % of the area that
presented these alterations. 0, no lesion; 1, b25% of parenchyma affect-
ed by the lesion; 2, 25–50% of parenchyma affected by the lesion; 3, 50–
75% of parenchyma affected by the lesion and 4, N75% of parenchyma
affected by the lesion.
2.5. Immunoﬂuorescence Staining
Kidneys were ﬁxed in 4% PLP (4% paraformaldehyde, 75 mM L-
lysine, 10 mM sodium periodate) for 2 h at 4 °C, and then placed in
30% sucrose overnight. Tissueswere snap frozen in optimal cutting tem-
perature compound (OCT, Sakura FineTek, Torrance, CA) and cryosec-
tions of 7 μM were mounted on microscope slides. Sections were
incubated overnight with primary antibodies as indicated: anti-F4/80
(hybridoma supernatant) and anti-GR1+ (eBioscience), or anti-
Kidney-speciﬁc cadherin (Ksp-cadherin) (Morizane et al., 2013). Slides
were then incubated with Cy3 or FITC labeled secondary antibodies
(Jackson ImmunoResearch). Sectionsweremounted in Vectashield con-
taining DAPI to stain the nuclei (VectorLabs, Burlingame, CA). Neutro-
phils were expressed as the mean number of GR1+ cells per 400×
magniﬁcation ﬁeld and macrophages as the mean per unit area of
F4/80 + cells in 400× magniﬁcation ﬁelds using ImageJ. Ksp-
cadherin positive area was also expressed as the mean of KSP stain
positive area in 200× magniﬁcation ﬁelds. Ten randomly selected
images per mouse were quantiﬁed using ImageJ software (http://
rsbweb.nih.gov/ij/) (Schrimpf et al., 2012; Grgic et al., 2012). All im-
ages were obtained by standard or confocal microscopy (Eclipse 90i,
C1 Eclipse, respectively; both from Nikon).
2.6. Quantitative RT-PCR
Total RNAwas isolated from cells or kidneys using the TRIzol reagent
(Sigma) according to the standard protocol. First-strand cDNAwas syn-
thesized using the MML-V reverse transcriptase (Promega, USA). Real-
time PCR was performed using the iQ-SYBR Green Supermix (BioRad)
and the iQ5 Multicolor Real-time PCR Detection System (BioRad) for
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mRNA expression was normalized to housekeeping genes, and relative
mRNA levels are expressed as fold change compared with the DMSO
treated cells or sham animals. Primers used were as follows: Rn18s for-
ward: ATGGCCGTTCTTAGTTGGTG, reverse: GAACGCCACTTGTCCCTCTA;
Havcr1 forward: AAACCAGAGATTCCCACACG, reverse: GTCGTGGGTCTT
CCTGTAGC; Tnf forward: CCCTGAGGGGGCTGAGCTCAA, reverse: ACCT
GCCCGGACTCCGCAAA; Il1b forward: CCTTCCAGGATGAGGACATGA, re-
verse: AACGTCACACACCAGCAGGTT; Il6 forward: TAGTCCTTCCTACCCC
AATTTCC, reverse: TTGGTCCTTAGCCACTCCTTC; Ccl2 forward: TGCATC
TGCCCTAAGGTCTTC, reverse: AAGTGCTTGAGGTGGTTGTGG; Nos2 for-
ward: ACCCTCCTCGTTCAGCTCACCTTC, reverse: TCGCTCCAAGATTCCC
TGCACCA; Hmox1 forward: TTCCCGAACATCGACAGCCCC, reverse:
AGCAGGAAGGCGGTCTTAGCCTC; Slc2a1 forward: GCTGTGCTTATGGG
CTTCTC, reverse: CACATACATGGGCACAAAGC; Pgk1 forward: GCCACT
TGCTGTGCCAAATG, reverse: CCCAGGAAGGACTTTACCTT; Hk2 forward:
GGACTGGACCGTCTGAATGT, reverse: ACAGTTCCTTCACCGTCTGG; Ldha
forward: GAAGATAAGTGGTTTTCCCAAAAAC-3 reverse: CTTTGAGTTT
GATCACCTCATAAGC and Actb forward: CCAACCGCGAGAGAGTGA, re-
verse: TCCATCACGATGCCAGTG.2.7. Assays of Mitochondrial Physiology
C57BL/6 mice were treated with two intraperitoneal injections of
100 mg/kg meclizine at 17 and 3 h before sacriﬁcing. Mitochondria
were isolated from kidneys by differential centrifugation and resus-
pended in experimental buffer containing glutamate and malate as re-
spiratory substrates (125 μM) to a ﬁnal concentration of 0.5 mg/ml
(Gohil et al., 2010). Coupled and uncoupled respiration was measured
following addition of 0.1 mM ADP and 5 μM carbonyl cyanide m-
chlorophenyl hydrazone, respectively. O2 consumption was monitored
with a Fiber Optic Oxygen Sensor Probe (Ocean Optics) at 25 °C.2.8. Electron Microscopy
Pieces of mouse kidney tissue were ﬁxed in 4% paraformaldehyde,
post-ﬁxed in 1% osmium tetroxide, dehydrated in graded alcohols, and
embedded in Epon. A tissue block of approximately 1 mm3 was collect-
ed from each kidney, including a portion of renal cortex and outer
medulla for standard processing. Semithin sections of each block were
stained with toluidine blue stain and examined by light microscopy to
select for ultrathin sectioning. Ultrathin sections were cut, placed on
nickel grids, and examined using a digital electron microscope (JEOL
USA JEM-1010).Mitochondrial areawasmeasured by using ImageJ soft-
ware (Birk et al., 2013).2.9. Cell Culture
TheHK-2 (human kidney-2; humanproximal epithelial cell) and LLC-
PK1 cells were purchased from the American Type Culture Collection.
Cells were cultured in DMEM or DMEM/F12 containing 10% fetal bovine
serum, in a humidiﬁed atmosphere with 5% CO2 at 37 °C.2.10. Cell Injury Models
Cells were treated with sodium cyanide (NaCN) (1.5 mM) and 2-
deoxyglucose (2-DG) (10 mM) to induce cellular stress and injury by
chemical anoxia. In this study, cells were seeded in 12-well plates at
0.5 × 105 cells/well or in 6 cm dishes at 2.5 × 105 cells/well, incubated
overnight, and pretreated with different concentrations of meclizine
(0, 10, 25 μM) or ethanolamine (0, 10, 100 μM) for 17 h. After 17 h pre-
conditioning with meclizine or ethanolamine, the cells were treated
with NaCN and 2-DG for 2 h.2.11. Measurement of Lactate Production
Increased lactate productionwas used as amarker of upregulation of
glycolysis. Brieﬂy, HK-2 cells were subcultured 1:4 from a conﬂuent cul-
ture plate into a 10 cm dish. Once conﬂuence was reached, cells were
treated with 25 μM of meclizine or vehicle for 17 h. After incubation
cells were washed and incubated in 1 ml PBS at 37 °C for 1 h, and
then incubated in 1 ml of PBS containing 1 mM glucose at 37 °C for
1 h. Samples were collected and 50 μl of 1.6 M perchloric acid was
added to 1 ml of PBS containing 1 mM glucose to stop metabolism.
Lactate productionwasmeasured at a wavelength of 340 nmafter incu-
bation of 100 μl of each sample with a 1 ml reaction buffer (0.1 M Tris,
0.4 M hydrazine, 0.4 mM EDTA, 10 mMMgSO4, 80 mg/ml NAD, LDH 5
mg/ml, pH 8.5) for 1 h at room temperature. Results were normalized
to the protein content of the sample.
2.12. LDH Assay
Cell viability after various treatments was evaluated by LDH micro-
plate titer assay as previously described (Chen et al., 1990). At the end
of various treatments, 100 μl of culture medium was collected to
measure media LDH levels. Then total LDH levels were determined by
addition of Triton X-100 (ﬁnal concentration 0.1%) to the cells at 37 °C
for 30 min to release all LDH. The percentage of LDH release was calcu-
lated by dividing the media LDH after a treatment by total LDH.
2.13. MTT Assay
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) tetrazolium reduction assay was performed as previously
described (Alley et al., 1988).
2.14. ATP Measurement
Cells were seeded into a 12 well plate (0.5 × 105 cells/well) and
allowed to grow overnight. Growth medium (DMEM or DMEM/F12
containing 10% fetal bovine serum)was then replaced with 25mMglu-
cose or 10 mM galactose medium and cells cultured for 24 h under 21%
or 5%O2 for 24 h. For themeclizine or ethanolaminepreconditioning ex-
periment, after incubation with 25 μM of meclizine, 10 μM ethanol-
amine or DMSO for 17 h growth medium was replaced with 10 mM
galactosemediumand cells were cultured for another 24 h. ATP content
was assessed using the ATP Bioluminescent Assay Kit (Sigma-Aldrich,
St. Louis, MO, USA) and normalized to total cellular protein.
2.15. Determination of the Intracellular Concentration
of Phosphoethanolamine
Intracellular concentration of phosphoethanolamine in meclizine-
treated HK-2 cells was determined as follows: HK-2 cells were seeded
into a 6 cm plate (0.25 × 106 cells/dish). After 20 h of growth, cells
were treated with 25 μM meclizine or DMSO for approximately 17 h.
Cells were scraped, collected in methanol extraction solution (80%
methanol, 20% H2O), and phosphoethanolamine levels were quantiﬁed
by liquid chromatography–mass spectrometry (LC–MS) (Gohil et al.,
2013).
2.16. Analysis of the Release of cytochrome c
To determine the cytochrome c released from mitochondria during
chemical hypoxia with or without meclizine pretreatment, cells were
permeabilized with 0.05% (wt/vol) digitonin in an isotonic sucrose
buffer for 2–4 min (Brooks et al., 2009). The cytosolic fraction released
by digitonin was collected for western blot analysis using speciﬁc anti-
bodies to cytochrome c.
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HIF1α stabilization and the release of cytochrome c were analyzed
by western blot analysis. Extracts (20 μg/lane protein) from cells
pretreated with either 0.1% DMSO, 25 μM meclizine or 500 μM CoCl2
(Sigma) or digitonin lysate, were separated by SDS-PAGE, transferredFig. 1. Pretreatment withmeclizine protects the kidney against IRI. (A) Scheme illustrating the s
animals pretreated 17 and 3 h before IRI with vehicle or various doses of meclizine. (C) Scheme
(D) Serum creatinine levels at 24 h after IRI, in animals pretreated with a one-time injection
pretreated 17 h before IRI with a one-time injection of 100 mg/kg of meclizine or vehicle. Sha
KIM-1mRNA (Havcr1) in sham, vehicle andmeclizine pretreatedmice at 48 h after IRI.Micewer
Sham (n= 3), IRI+Veh (n= 4) and IRI+meclizine (n= 4). (G) Representative images after
after IRI. Original magniﬁcation 200 ×, scale bar = 100 μm. (H) Tubular necrosis was semi-qua
(n=8). ***p b 0.001; **p b 0.01 and *pb 0.05. Statistical signiﬁcancewas determinedusing one-
SEM.onto a PVDF membrane, and subjected to Western blotting using anti-
HIF-1α (Novus Biologicals, Littleton, CO), anti-cytochrome c (BD
Pharmingen, San Diego, CA), or anti-β-actin (Cell signaling), antibodies.
β-actin was used as a loading control. Proteins were visualized using
HRP-conjugated secondary antibodies (Dako, Glostrup, Denmark) and
ECL detection reagents (GE Healthcare, Milwaukee, WI). The ECL ﬁlmtrategy for the dose–response experiments. (B) Serum creatinine levels at 24 h after IRI, in
illustrating the strategy comparing effectiveness of treatment at various times prior to IRI.
of meclizine at different time-points before IRI. (E) BUN levels at 24 h after IRI in mice
m (n = 3), IRI+Veh (n = 8) and IRI+meclizine (n = 8). (F) Real-time PCR analysis of
e pretreated 17 h before IRIwith a one-time injection of 100mg/kg ofmeclizine or vehicle.
hematoxylin and eosin (H & E) and Periodic acid-Schiff (PAS) staining of tissue taken 48 h
ntiﬁed by scoring H&E stained slides. Sham (n= 3), IRI+Veh (n= 8) and IRI+meclizine
wayANOVA followed by Tukey's post-hoc test. The columns and error bars are themean±
1094 S. Kishi et al. / EBioMedicine 2 (2015) 1090–1101was scanned using a commercial ofﬁce scanner (Epson Expression 1680
Scanner) and evaluated in ImageJ.
2.18. Statistical Analysis
Statistical analysis was performed using Prism 6.0 (GraphPad Soft-
ware Inc.). Evaluation of the data was carried out using the unpaired
two-tailed t test when two groups were compared or one-way Analysis
of Variance (ANOVA) followed by Tukey's post-test when multiple
groups were compared. A p value lower than 0.05 was considered to
be signiﬁcant. Statistical power analyses were performed to evaluate
sample numbers necessary for the main group comparisons reﬂected
in Fig. 1B and D. Animal number in each groupwas chosen to have a sta-
tistical power higher than 0.80 (Cohen, 1992; Faul et al., 2007, 2009).
When not speciﬁcally stated results are presented as means of at least
three independent experiments and error bars indicate ±SEM.
3. Results
3.1. Pretreatment With Meclizine Protects the Kidney Against IRI
To evaluate whether meclizine pretreatment protects the kidney
against IRI, we treatedmice twice, 17 and 3 h before 27min of ischemia,
with different doses of meclizine and analyzed kidney function 24 h
after surgery (Fig. 1A). A ﬂow diagram for the meclizine dose–
response experiments is presented in Supplementary Fig. 1. Serum cre-
atinine levels were increased in mice subjected to IRI, reﬂecting kidney
dysfunction (Fig. 1B). There was a dose-dependent protection afforded
by meclizine which was statistically signiﬁcant at the 100 mg/kg dose
level. At this dose of meclizine serum creatinine levels were 0.90 ±
0.10 (mean ± SEM) mg/dl in the meclizine-treated group vs 1.40 ±
0.20 mg/dl in the vehicle group (p b 0.01) (Fig. 1B). In a second set of
animals meclizine (100 mg/kg) was administered at different time
points before IRI (Fig. 1C). A ﬂow diagram for themeclizine time course
experiments is presented in Supplementary Fig. 2. Kidney function was
analyzed 24 h after surgery. KIM-1 mRNA (Havcr1) levels and histology
were evaluated 48 h after surgery. When mice were treated with only
one dose ofmeclizine (100mg/kg) 17 or 24 h before IRI, therewas a sig-
niﬁcant decrease in creatinine levels 24 h after reperfusion compared to
the respective vehicle-treated group (17 h pretreatment: 0.89± 0.11 vs
1.59 ± 0.10 mg/dl, p b 0.001; 24 h pretreatment: 0.60 ± 0.17 vs 1.50±
0.25mg/dl, p b 0.05) (Fig. 1D). Therewas no difference in the amount of
body weight loss between the vehicle and meclizine (100 mg/kg 17 h
before IRI) treated mice 24 h after IRI (vehicle 24.35 ± 0.4 to 22.45 ±
1.03 g, meclizine: 24.90 ± 0.74 to 22.13 ± 0.69 g) or in weights 48 h
after vehicle or meclizine administration at 17 and 3 h prior to IRI
(23.60 ± 0.40 g, vehicle; 23.88 ± 0.38 g, meclizine). Pretreatment for
8 h before ischemia resulted in decreased serum creatinine levels 24 h
after reperfusion but this difference failed tomeet statistical signiﬁcance
when compared to the vehicle-treated group (Fig. 1D). Blood urea nitro-
gen (BUN) levels were also decreased in the group treated 17 h before
injury with 100 mg/kg meclizine in comparison to the vehicle group
(90± 10 vs 122± 7mg/dl, p b 0.05) (Fig. 1E). In addition to serum cre-
atinine and BUN, there was less upregulation of Havcr1 mRNA in the
48 h post-IRI kidney from mice pretreated 17 h prior to ischemia with
meclizine (123 ± 14 fold increase) when compared to vehicle-treated
mice (311 ± 22 fold increase; p b 0.001) (Fig. 1F). Pretreatment with
meclizine (100 mg/kg) 17 h before IRI reduced tubular necrosis score
when compared to the vehicle-treated IRI group (2.5 ± 0.1 vs, 3.8 ±
0.1 p b 0.001) (Fig. 1G, H).
3.2. Inﬂammation After IRI Is ReducedWithMeclizine (100mg/kg) Pretreat-
ment 17 h prior to IRI
Because inﬂammation contributes to IRI, we analyzed inﬂammatory
cell inﬁltration and cytokine production 48 h after IRI in animalspretreated with meclizine or vehicle. As expected, there was an in-
crease in GR-1+ neutrophils and F4/80+ macrophage inﬁltration
in the kidney subjected to IRI, as well as an increase in tissue
mRNA levels of inﬂammatory mediators: Il1b, Tnf, Il6 and Ccl2
when compared to vehicle-treated sham non-ischemic animal kid-
neys (Fig. 2). In meclizine pre-treated animals there were fewer in-
ﬁltrating neutrophils 48 h after ischemia (1.5 ± 0.1 vs 3.6 ± 0.8 cells
per high power ﬁeld, p b 0.05) (Fig. 2A and B). There was also a trend
toward reduced numbers of inﬁltrating F4/80+ macrophages
(Fig. 2C). Meclizine pretreatment resulted in reduced fold-
increases in mRNA expression of inﬂammatory cytokines Il1b
(4.38 ± 0.96 vs 7.80 ± 0.83 (vehicle-treated) p b 0.05), Tnf
(1.89 ± 0.65 vs 8.47 ± 2.00, p b 0.01), Il6 (40 ± 16 vs 164 ± 39,
p b 0.05) and the chemokine Ccl2 (5.6 ± 1.0 vs 12.8 ± 2.2,
p b 0.05) (Fig. 2D–G). Thus the protection afforded by pretreatment
with meclizine reduced inﬂammation after IRI.3.3. Meclizine Inhibits Mitochondrial Respiration and Reduces Kidney
Injury After IRI
We tested meclizine as a potential therapeutic agent for kidney IRI
based on its previously reported activity as mitochondrial respiration
attenuating agent. While earlier work (Gohil et al., 2010, 2013) has
clearly shown that meclizine attenuates mitochondrial respiration
in an in vitro cell culture system, it is not known whether meclizine
would attenuate respiration when administered to a whole organ-
ism. Therefore, to test the effect of meclizine on kidney respiration,
mitochondria were isolated from the kidneys of mice pretreated
with meclizine. Mice were treated with two doses of meclizine
(100 mg/kg), 17 h and 3 h before sacriﬁce. Kidney mitochondria iso-
lated frommice that receivedmeclizine, had decreased O2 consump-
tion after ADP addition and a further decrease after exposure to the
uncoupling agent carbonyl cyanide 3-chlorophenylhydrazone
(CCCP), when compared with kidney mitochondria isolated from
vehicle-treated mice (Fig. 3A).
Heme-oxygenase-1 (Hmox1) and inducible nitric oxide synthase
(Nos2) are up-regulated after kidney injury, related to IR-induced
oxidative stress (Aragno et al., 2003; Szeto et al., 2011). As expected,
the kidney mRNA expression levels were up-regulated 24 h after IRI
in both meclizine and vehicle-treated animals. Meclizine-pretreated
mice subjected to IRI showed lower fold-increases of Hmox1 (7.09 ±
2.01 fold) when compared with the vehicle-treated group (13.3 ±
1.87 fold) (p b 0.05) and lower increases in Nos2 (1.17 ± 0.35, in
the meclizine group vs 2.94 ± 0.74 in the vehicle-treated control
group, p b 0.05), indicating a reduced oxidative stress (Fig. 3B and
C). To check the number of viable tubular cells after IRI, we evaluated
Kidney-speciﬁc cadherin (Ksp-cadherin) expression (Thomson
et al., 1995). When tubular cells are damaged, the number of Ksp-
cadherin positive tubular cells is decreased (Morizane et al., 2014).
Ischemia led to a decrease in the normalized number of Ksp-
cadherin positive tubular cells, but meclizine pretreatment partially
mitigated this decreased expression (0.32 ± 0.05 in the vehicle
group vs 0.74 ± 0.12 in the meclizine-treated group, when normal-
ized to sham-treatedmice, p b 0.05) (Fig. 3D and E). Electronmicros-
copy revealed loss of brush borders of proximal tubule cells with
extensive damage to the mitochondria which is reﬂected by round
and fragmented mitochondria after IRI in vehicle-treated mice
(Fig. 3F and G) (Brooks et al., 2009). In contrast, the representative
images from a meclizine-pretreated kidney (Fig. 3H and I) showed
intact brush borders and many elongated mitochondria on the
basal side of the tubular cells. Mean mitochondrial area is 2.73 ±
0.43 times greater in the vehicle vs meclizine pretreated kidney
(p b 0.01) (Fig. 3J). These data revealed that meclizine reduced tubu-
lar damage-induced oxidative stress and inhibited IRI-inducedmito-
chondrial structural changes.
Fig. 2. Inﬂammation after IRI is reduced with meclizine (100mg/kg) pretreatment 17 h prior to ischemia. (A) Representative images of GR1+ (neutrophils) and F4/80 (macrophages)
stained kidneys from sham, vehicle and meclizine pretreated mice at 48 h after IRI. Original magniﬁcation 400 ×, scale bar = 20 μm. (B and C) Quantiﬁcation of GR1+ positive cells
and F4/80 positive area. (D–G) Real-time PCR analysis of Il1b, Ccl2, Tnf and Il6mRNA in sham, vehicle and meclizine pretreated mice at 48 h after IRI. Sham (n = 3), IRI+Veh and IRI+-
meclizine (n=4 to 6). ***p b 0.001; **p b 0.01 and *p b 0.05. Statistical signiﬁcance was determined using one-way ANOVA followed by Tukey's post-hoc test. The columns and error bars
are the mean ± SEM.
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of AKI
To evaluate whether meclizine would also be protective when
given after the injury had been already established, we treated
mice with 100 mg/kg of meclizine twice, one injection right after
reperfusion and a second injection 8 h after IRI. No signiﬁcant differ-
ences were measured in serum creatinine levels, tubular necrosis
score or kidney KIM-1 mRNA (Havcr1) expression between the ve-
hicle and meclizine-treated group after IRI (Fig. 4A–D). There was
also no difference in the tissue mRNA expression of inﬂammatory
mediators (Fig. 4E). Thus protection by meclizine was limited to
preconditioning.We also tested whether preconditioning with meclizine was effec-
tive in two toxicity models of AKI. Mice were treated with meclizine
17 h or 1 h before the injection of aristolochic acid or cisplatin. Serum
creatinine and urinary KIM-1weremeasured at the peak of the toxic in-
jury, 5 days after aristolochic acid injection or 3 days after cisplatin in-
jection. Mice injected with aristolochic acid had increases in serum
creatinine levels and urinary KIM-1 compared to sham control mice.
In contrast to the protection observed with meclizine preconditioning
in the IRI model, pretreatment with meclizine either 17 h or 1 h before
aristolochic acid injection had no effect on creatinine and urinary KIM-1
levels (Fig. 4F, G). Mice injected with cisplatin had signiﬁcant increases
in serum creatinine and urine KIM-1 levels, neither of which was mod-
iﬁed by meclizine pretreatment (Fig. 4H, I).
Fig. 3.Meclizine inhibitsmitochondrial respiration and reduces kidney IRI. (A) Oxygen consumptionwasmeasured inmitochondria isolated from kidneys ofmice treatedwith two doses
of 100mg/kg meclizine (Mec), 17 and 3 h before sacriﬁce. Traces are representative of three independent experiments, each performed in triplicate. Mitochondria (Mitos),
ADP and carbonyl cyanide m-chlorophenyl hydrazone (CCCP) were added at the indicated time points. Antimycin was used to inhibit respiration. (B and C) Real-time PCR
analysis of Hmox1 and Nos2 mRNA in sham, vehicle and meclizine pretreated mice at 48 h after IRI. (D) Representative images of Ksp-cadherin stained kidneys from sham,
vehicle and meclizine pretreated mice at 48 h after IRI. Original magniﬁcation 200 ×, scale bar = 20 μm.(E) Quantiﬁcation of Ksp-cadherin positive area. Original magniﬁca-
tion 200×, scale bar = 20 μm. (F–I) Representative electron microscopic images of mitochondria in proximal tubular cells at 24 h after IRI obtained from vehicle or meclizine-
treated kidneys 17 h before IRI. A red arrow indicates the brush borders and a white arrowhead indicates mitochondria. (J) Quantiﬁcation of mitochondrial area. n = 3 sham,
n = 3 to 8 IRI+Veh and IRI+meclizine, ****p b 0.0001; ***p b 0.001; **p b 0.01 and *p b 0.05. Statistical signiﬁcance was determined using one-way ANOVA followed by
Tukey's post-hoc test (B, C, E) or t test (J). The columns and error bars are the mean ± SEM. Scale bar = 2 μm.
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NaCN Treatment of Tubular Epithelial Cells
To evaluate whether meclizine protected kidney tubular epithelial
cells in vitro, cells were pretreatedwithmeclizine 17 h prior to chemical
anoxia induced by 1.5 mM of NaCN and 10 mM of 2-DG. A signiﬁcant
decrease of % LDH release in LLC-PK1 and HK-2 cells was observed in
cells pretreated with 25 μM of meclizine when compared with cells
pretreated with DMSO only (LLC-PK1 cells, 11.6 ± 3.2% vs 25.9 ± 1.5,
p b 0.01, Fig. 5A, HK-2 cells, 27.0 ± 5.9 vs 47.6 ± 6.3%, p b 0.05,
Fig. 5B, respectively). Furthermore meclizine pretreatment blocked
the release of injury-associated cytochrome c from HK-2 cells exposed
to chemical anoxia (Fig. 5C, D).3.6. Meclizine Up-regulates Glycolysis in Glucose Containing Media and
Reduces Cellular ATP Levels in Galactose Media
Culturing cells in galactose as a sugar source forces mammalian cells
to rely on mitochondrial oxidative phosphorylation (OXPHOS) (Aguer
et al., 2011; Gohil et al., 2010). LDH releasewas increased and cell viabil-
ity was reduced in galactose media when oxygen was decreased from
21 to 5%. A signiﬁcant increase in % LDH release and decrease in cell vi-
ability were observed in cells cultured in 5% O2 with 10 mM galactose
when compared with cells cultured in 5% O2 with 25 mM glucose (%
LDH release: 33.0± 3.89 vs 15.7± 0.24%, p b 0.05, Fig. 6A; cell viability:
12.0 ± 4.23 vs 65.1 ± 2.83%, p b 0.01, Fig. 6B). Cellular ATP levels also
decreased when cells were cultured in 5% O2 with 10 mM galactose vs
Fig. 4.Meclizine is not protective if given after IRI or in two toxicity models of AKI. (A) Serum creatinine levels at 24 h after ischemia in mice treated with two injections of meclizine
(100 mg/kg; given right after reperfusion and 8 h after reperfusion). (B) Representative images of H&E staining at 48 h after ischemia. Scale bar = 100 μm. (C) Tubular necrosis was
semiquantiﬁed by scoring H&E stained slides. (D) KIM-1 mRNA (Havcr1) expression at 48 h after IRI relative to revels in sham kidneys. (E) Ccl2, Tnf, and Il1bmRNAs expression at 48 h
after ischemia relative to revels in sham kidneys. n = 3 sham, n= 3 to 4 IRI+Veh and IRI+meclizine. (F) Serum creatinine and (G) urinary KIM-1 levels at 5 days following aristolochic
acid (AA) injection inmice pretreatedwith orwithoutmeclizine (Mec) 17 h or 1 h before injection. n= 2 sham, n= 5 AA+Veh and AA+meclizine. (H) Serum creatinine and (I) urinary
KIM-1 levels at 3 days following cisplatin (Cis) injection inmice pretreatedwith orwithoutmeclizine. sham (n=2), Cis+Veh and Cis+meclizine (n=3); ns=not signiﬁcant. Statistical
signiﬁcance was determined using one-way ANOVA followed by Tukey's post-hoc test. The columns and error bars are the mean ± SEM. Scale bar = 100 μm.
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tein, p b 0.05, Fig. 6C). Thus culturing cells with galactose as an energy
source forces kidney tubular epithelial cells to rely on mitochondrial
oxidative respiration rather than glycolysis.
To evaluate whether pretreatment with meclizine affected energy
metabolism in vitro, lactate production of HK-2 cells was analyzed. Mec-
lizine pretreatment for 17 h in 21% O2 increased lactate production
(51.61±8.05 vs 25.87±3.67 nmol/h/mg, p b 0.05) in glucose containing
media (Fig. 6D). Meclizine pretreatment increased the mRNA levels of
representative enzymes of glycolysis, hexokinase 2 (Hk2), phosphoglyc-
erate kinase 1 (Pgk-1) and lactate dehydrogenase-A (Ldha) (Fig. 6E).
Meclizine pretreatment also decreased ATP levels in HK-2 cells grown in
galactose containing media for 24 h (2.3 ± 0.12 vs 3.1 ± 0.14 nmol/mgprotein, p b 0.05) (Fig. 6F). We did not observe HIF1-α stabilization
following meclizine pretreatment. As a positive control, CoCl2 pretreat-
ment induced HIF1-α stabilization (Fig. 6G and H). Taken together,
these ﬁndings suggest that meclizine is capable of shifting reliance to
glycolysis relative to mitochondrial respiration in a HIF1-α independent
manner on HK-2 cells. Despite this decrease in cellular ATP levels, the
meclizine-pretreated cells were protected against injury (Fig. 5A–D).
3.7. Cellular Phosphoethanolamine Is Increased by Meclizine and Recapitu-
lates Meclizine-induced Protection
It has been shown that meclizine attenuated mitochondrial respira-
tion by targeting cytosolic phosphoethanolamine metabolism (Gohil
Fig. 5.Meclizine attenuates LDH and cytochrome c release during 2-DG and NaCN treatment of tubular epithelial cells. (A) LDH release from LLC-PK1 cells treated with different concen-
trations of meclizine for 17 h followed by 2hr of chemical anoxia (n = 3). (B) LDH release from HK-2 cells treated with different concentrations of meclizine for 17 h followed by 2hr of
chemical anoxia (n= 7). (C) Western blot shows released cytochrome c from HK-2 cells after chemical anoxia in the presence or absence of meclizine pretreatment. (D) Quantitation of
the band density of cytochrome c (n= 3). *p b 0.05. Statistical signiﬁcance was determined using one-way ANOVA followed by Tukey's post-hoc test. The columns and error bars are the
mean ± SEM.
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asked whether the protective effect of meclizine pretreatment on kid-
ney IRI ismediated through this pathway. As shown in Fig. 7A,meclizine
pretreatment increased intracellular phosphoethanolamine in HK-2
cells (6.0±0.62 vs 2.1±0.10 μM,p b 0.05). Ethanolaminepretreatment
signiﬁcantly decreased ATP levels when cells were cultured in galac-
tose-containing medium (3.0 ± 0.48 vs 5.2 ± 0.54 nmol/mg protein,
p b 0.05) and was associated with increased lactate production
(37.57 ± 12.71 vs 24.50 ± 3.18 nmol/h/mg, although not statistically
signiﬁcant p = 0.3352) (Fig. 7B, C). Ethanolamine pretreatment also
inhibited % LDH release in response to 1.5 mM of NaCN and 10 mM of
2-DG-induced chemical hypoxia in HK-2 cells (10 μM: 23.9 ± 4.6 vs
49.0 ± 4.2%, p b 0.01 and 100 μM: 28.9 ± 5.2 vs 49.0 ± 4.2%, p b 0.05)
and LLC-PK1 cells (10 μM; 39.1 ± 1.84 vs 65.0 ± 4.39%, p b 0.05)
(Fig. 7D, E). When ethanolamine was given 2 h before ischemia, imme-
diately after and 24 h after reperfusion, there was a signiﬁcant decrease
in BUN levels in mice exposed to IRI when compared to the vehicle
group (24 h: 88.23 ± 12.23 vs 133.6 ± 7.15 mg/dl, p b 0.05; 48 h:
84.13±19.62 vs 150.8±12.26mg/dl, p b 0.05). Serumcreatinine levels
at 24 h after IRI were also lower (1.25 ± 0.24 vs 1.94 ± 0.09 mg/dl,
p b 0.05) (Fig. 7F, G). Compared with vehicle-injected mice, the renal
morphology of ethanolamine-injected mice showed less kidney injury
(Fig. 7H). These data revealed that phosphoethanolamine recapitulated
meclizine-induced protection both in vitro and in vivo.
4. Discussion
Meclizine is an attractive potential therapeutic agent for IRI, since it
is well established to be safe in humans and it has an unusual mecha-
nism of protection. Meclizine inhibits mitochondrial respiration. Mecli-
zine decreases post-ischemic serum creatinine levels when given at
least 17 h before injury. The fact that prolonged pretreatment is neces-
sarywouldmake this safe drug appropriate for situationswhere there is
a predictable increase in the probability of developing AKI, such ascardiac surgery, ICU stay or perhaps during allograft preservation prior
to transplantation.
The shift in cellular energy production from mitochondrial respira-
tion, which consumes oxygen, to anaerobic glycolysis, is a natural adap-
tation to reduced oxygen availability (Ramirez et al., 2007). Redirecting
energy metabolism toward anaerobic glycolysis can reduce ischemia-
induced ROS production, oxidative damage and suppress apoptosis
(Vaughn and Deshmukh, 2008; Jeong et al., 2004). We have shown
that meclizine attenuates mitochondrial respiration likely through
increase in cellular phosphoethanolamine and increases mRNA levels of
glycolytic enzymes and lactate production. Signiﬁcantly lowered expres-
sion of post-ischemic HO-1 and iNOS in meclizine-treated mice reﬂect
decreased oxidative stress caused by IRI (Birk et al., 2013; Jeong et al.,
2004). This protective effect is brought about by a HIF-independent
mechanism (Gohil et al., 2010, 2013). Thus FDA-approved meclizine
shifts energy metabolism (Gohil et al., 2010) and may be a useful candi-
date for chemical ischemic preconditioning in kidney. While the doses
used here are high, more effective agents may be developed which can
be used at lower concentrations with potentially fewer off-target effects.
Reducing inﬂammation has been shown to be important for a better
outcome in IRI-related organ damage (Mauriz et al., 2001; Meng et al.,
2001). Meclizine pretreatment of mice attenuates IRI-induced kidney
tubular damage and is associated with a reduction of inﬂammation in-
cluding a reduction in granulocytes and expression of a number of cyto-
kine genes, all of which are well established to contribute to the post-
ischemic inﬂammatory milieu (Szeto et al., 2011) (Kielar et al., 2005)
(Kreisel et al., 2011).
Postischemic structural and functional changes in mitochondria are
closely linked (Kaasik et al., 2007). IRI in kidney induces fragmentation
of mitochondria which leads to sustained energetic deﬁcits, release of
cytochrome c, and activation of cell death pathways in proximal tubule
epithelial cells (Brooks et al., 2009; Barsoum et al., 2006). We have
shown that meclizine attenuates mitochondrial structural changes and
release of cytochrome c.
Fig. 6.Meclizine up-regulates glycolysis in glucose containingmedia and reduces cellular ATP levels in galactosemedia. (A) LDH release, (B) Cell viability and (C) cellular ATP levels of LLC-
PK1 cells cultured under 21% or 5%O2with 25mMglucose or 10mMgalactose for 24 h (n=3). (D) Lactate production inHK-2 cells after treatmentwith orwithout 25 μMofmeclizine for
17 h in 21% O2 and glucose containing media (n = 4). (E) Real-time PCR analysis of Slca2, Pgk1, Hk2 and LdhamRNA after treatment with or without 25 μM of meclizine for 17 h (n= 3).
(F) Cellular ATP levels inHK-2 cells treatedwith orwithout 25 μMofmeclizine for 17 h and then culturedwith 10mMgalactose (n=3). (G)Western blot displays protein level of HIF1-α
after meclizine or CoCl2 pretreatment. (H) Quantitation of the band density of HIF1-α (n= 3). **p b 0.01 and *p b 0.05. Statistical signiﬁcance was determined using t test (D, E, F) or one-
way ANOVA followed by Tukey's post-hoc test (A, B, C, H). The columns and error bars are the mean ± SEM.
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initial injury. Acute exposure tomeclizinedid not decreaseO2 consump-
tion on kidney mitochondria isolated from mice (Gohil et al., 2010). By
contrast when mice received meclizine 17 h before IRI there was a de-
crease in isolated mitochondrial O2 consumption. Thus meclizine must
be present prior to an insult to be effective for the reduction of mito-
chondrial respiration. Meclizine inhibits phosphate cytidylyltransferase
2 (PCYT2) and causes an increase in cytosolic phosphoethanolamine, an
ethanolaminederivative that is a central precursor in the biosynthesis of
membrane phospholipids (Gohil et al., 2013). High levels of intracellular
phosphoethanolamine inhibit mitochondrial respiration (Gohil et al.,
2013;Modica-Napolitano and Renshaw, 2004). Ethanolamine, a precur-
sor of phosphoethanolamine, also inhibitsmitochondrial respiratory ac-
tivity (Modica-Napolitano and Renshaw, 2004; Gohil et al., 2013). In
this study we show that meclizine pretreatment increases intracellular
phosphoethanolamine in HK-2 cells and ethanolamine has protective
effects both in vitro in renal epithelial cells and in vivo in the kidney.
Thus a renoprotective effect of meclizine may be mediated by accumu-
lation of intracellular phosphoethanolamine (Fig. 7I).
While the dose used in these studies is higher than the dose used clin-
ically in humans there was nomeclizine inducedweight loss or other ev-
idence for toxicity in mice at these doses (Gohil et al., 2010). At the dose
used in this study mice are protected against acetaminophen-induced
liver toxicity (Huang et al., 2004). Although meclizine is classiﬁed as a
histamine (H1) antagonist and a muscarinic acetylcholine receptorantagonist, the other 64 annotated H1 receptor antagonists and 33 anno-
tated muscarinic antagonists in the original chemical library screen had
no effect on oxygen consumption (Gohil et al., 2010). It is likely that the
renal protective effect is independent of histaminergic or muscarinic sig-
naling or HIF-stabilization. This study justiﬁes the further development
of meclizine-like agents that can be selected for their mitochondrial
effects and given to humans to affect mitochondrial respiration while
minimizing anti-histaminergic and anticholinergic effects and main-
taining efﬁcacy in protecting against kidney injury.
We did not measure blood pressure. Althoughwe closely monitored
and tightly controlled the body temperature between 36.5 and 37 °C
and the technical success of ischemia–reperfusion by checking the kid-
ney color after clamping and after removing the clips (Park et al., 2004;
Wei andDong, 2012),we cannot completely exclude the possibility that
altered hemodynamicsmay contribute to a modiﬁcation of kidney inju-
ry after ischemia-reperfusion.
In conclusion, we have shown that pretreatment with 100 mg/kg of
meclizine 17 or 24 h prior to ischemia protectedmice from IRI. Meclizine
reduced mitochondrial oxygen consumption, and attenuated oxidative
stress and mitochondrial fragmentation after IRI. Meclizine induced in-
tracellular phosphoethanolamine accumulation which inhibits mito-
chondrial respiration. These ﬁndings suggest that pretreatment with
meclizine, or a derivative, may reduce kidney injury induced by shock,
sepsis, cardiovascular surgery and early allograft dysfunction. Further
studies of efﬁcacy are required to rigorously determine optimal dosing
Fig. 7. Cellular phosphoethanolamine is increased by meclizine and recapitulated meclizine-induced protection. (A) Phosphoethanolamine levels in HK-2 cells treated with or without
25 μM of meclizine for 17 h (n = 3). (B) Cellular ATP levels in HK-2 cells cultured in 10% DMEM containing 10 mM galactose with or without 10 μM of ethanolamine (EA) for 17 h
(n = 4). (C) Lactate production in HK-2 cells after treatment with or without 10 μM of EA for 17 h (n = 7). (D) LDH release from HK-2 cells treated with either 10 or 100 μM of EA for
17 h followed by 2 hr of chemical anoxia (n = 7). (E) LDH release from LLC-PK1 cells treated with 10 μM of EA for 17 h followed by 2 hr of chemical anoxia (n = 4). (F) BUN and
(G) serum creatinine concentrations at 24 and 48 h after IRI treated 2 h before, just after clamp removal and skin closure 24 h after ischemia with vehicle (n = 5) or EA (n = 4).
(H) Representative images of H&E and PAS-stained kidney sections 48 h after IRI. Original magniﬁcation 100 ×, scale bar = 100 μm. (I) Summary of the mechanisms proposed for mec-
lizine-induced protective effects against ischemic injury. Meclizine inhibits phosphate cytidylyltransferase 2 (PCYT2) and causes an increase in cytosolic phosphoethanolamine, a central
precursor in the Kennedy pathway. High levels of intracellular phosphoethanolamine inhibit mitochondrial respiration. **p b 0.01 and *p b 0.05. Statistical signiﬁcance was determined
using t test (A, B, C, F, G) or one-way ANOVA followed by Tukey's post-hoc test (D, E). The columns and error bars are the mean ± SEM.
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in humans.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.07.035.
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